Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Affimed N.V. (AFMD)

0.7535   -0.012 (-1.5%) 03-22 12:16
Open: 0.76 Pre. Close: 0.765
High: 0.78 Low: 0.75
Volume: 178,388 Market Cap: 113(M)

Technical analysis

as of: 2023-03-22 11:44:13 AM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.1     One year: 1.24
Support: Support1: 0.74    Support2: 0.61
Resistance: Resistance1: 0.94    Resistance2: 1.07
Pivot: 0.81
Moving Average: MA(5): 0.76     MA(20): 0.84
MA(100): 1.37     MA(250): 2.31
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 8.1     %D(3): 9.2
RSI: RSI(14): 28.3
52-week: High: 5.09  Low: 0.74
Average Vol(K): 3-Month: 1,218 (K)  10-Days: 814 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AFMD ] has closed above bottom band by 19.7%. Bollinger Bands are 57.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.79 - 0.79 0.79 - 0.79
Low: 0.73 - 0.74 0.74 - 0.74
Close: 0.76 - 0.76 0.76 - 0.77

Company Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Headline News

Thu, 16 Mar 2023
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023 - Yahoo Finance

Sat, 11 Mar 2023
Institutional owners may consider drastic measures as Affimed N.V.'s (NASDAQ:AFMD) recent US$21m drop adds to long-term losses - Simply Wall St

Wed, 08 Mar 2023
Affimed (NASDAQ:AFMD) Given Consensus Recommendation of ... - MarketBeat

Mon, 06 Mar 2023
Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq

Wed, 22 Feb 2023
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell ... - The Bakersfield Californian

Fri, 17 Feb 2023
Affimed (AFMD) Shifts Attention To Risky Combination Therapy - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 149 (M)
Shares Float 129 (M)
% Held by Insiders 3.5 (%)
% Held by Institutions 63.2 (%)
Shares Short 3,780 (K)
Shares Short P.Month 3,140 (K)

Stock Financials

EPS -0.57
EPS Est Next Qtl -0.21
EPS Est This Year -0.84
EPS Est Next Year -0.8
Book Value (p.s.) 1.21
Profit Margin (%) -180.6
Operating Margin (%) -195.9
Return on Assets (ttm) -22.5
Return on Equity (ttm) -48.1
Qtrly Rev. Growth 68.6
Gross Profit (p.s.) 0.27
Sales Per Share 0.28
EBITDA (p.s.) -0.55
Qtrly Earnings Growth 0
Operating Cash Flow -102 (M)
Levered Free Cash Flow -68 (M)

Stock Valuations

PE Ratio -1.32
PEG Ratio 0
Price to Book value 0.61
Price to Sales 2.67
Price to Cash Flow -1.11

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.